Global Retirement Partners LLC Has $9.96 Million Position in Abbott Laboratories $ABT

Global Retirement Partners LLC raised its position in shares of Abbott Laboratories (NYSE:ABT) by 20.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 79,525 shares of the healthcare product maker’s stock after purchasing an additional 13,576 shares during the quarter. Global Retirement Partners LLC’s holdings in Abbott Laboratories were worth $9,964,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the company. KDT Advisors LLC raised its stake in Abbott Laboratories by 16.3% during the 4th quarter. KDT Advisors LLC now owns 4,018 shares of the healthcare product maker’s stock valued at $503,000 after purchasing an additional 563 shares during the period. Mach 1 Financial Group LLC grew its holdings in shares of Abbott Laboratories by 283.8% during the 4th quarter. Mach 1 Financial Group LLC now owns 7,508 shares of the healthcare product maker’s stock valued at $941,000 after acquiring an additional 5,552 shares in the last quarter. Shakespeare Wealth Management LLC purchased a new position in shares of Abbott Laboratories during the 4th quarter valued at $259,000. Aspen Investment Management Inc grew its holdings in shares of Abbott Laboratories by 131.1% during the 4th quarter. Aspen Investment Management Inc now owns 13,258 shares of the healthcare product maker’s stock valued at $1,661,000 after acquiring an additional 7,520 shares in the last quarter. Finally, Burling Wealth Partners LLC grew its holdings in shares of Abbott Laboratories by 3.0% during the 4th quarter. Burling Wealth Partners LLC now owns 87,460 shares of the healthcare product maker’s stock valued at $10,958,000 after acquiring an additional 2,548 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ABT has been the topic of several research analyst reports. Stifel Nicolaus lowered their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, April 17th. JPMorgan Chase & Co. lowered their price target on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Wells Fargo & Company lowered their price target on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Mizuho lowered their price target on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Finally, TD Cowen lowered their price target on shares of Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $119.43.

Abbott Laboratories Trading Down 0.5%

Shares of NYSE:ABT opened at $88.38 on Thursday. The stock has a market capitalization of $153.93 billion, a PE ratio of 24.76, a P/E/G ratio of 1.48 and a beta of 0.65. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $139.06. The firm has a fifty day moving average price of $97.65 and a 200 day moving average price of $112.47.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The business’s revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Analysts expect that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.9%. Abbott Laboratories’s payout ratio is currently 70.59%.

Insider Activity

In other news, CFO Philip P. Boudreau bought 2,200 shares of the business’s stock in a transaction on Thursday, April 23rd. The stock was purchased at an average price of $91.50 per share, with a total value of $201,300.00. Following the transaction, the chief financial officer directly owned 2,200 shares in the company, valued at approximately $201,300. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Mary K. Moreland sold 613 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $70,850.54. Following the transaction, the executive vice president directly owned 104,291 shares of the company’s stock, valued at approximately $12,053,953.78. This represents a 0.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 3,055 shares of company stock worth $353,097. Insiders own 0.46% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.